Invesco Ltd. raised its position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 21.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 116,388 shares of the company's stock after purchasing an additional 20,882 shares during the period. Invesco Ltd. owned 0.61% of USANA Health Sciences worth $4,177,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of USNA. Wells Fargo & Company MN boosted its holdings in USANA Health Sciences by 35.4% during the 4th quarter. Wells Fargo & Company MN now owns 7,961 shares of the company's stock valued at $286,000 after acquiring an additional 2,082 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in USANA Health Sciences during the 4th quarter worth about $206,000. Geode Capital Management LLC boosted its position in shares of USANA Health Sciences by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 301,949 shares of the company's stock worth $10,839,000 after acquiring an additional 4,829 shares in the last quarter. Franklin Resources Inc. raised its position in shares of USANA Health Sciences by 4.8% during the 4th quarter. Franklin Resources Inc. now owns 22,070 shares of the company's stock worth $792,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in USANA Health Sciences in the fourth quarter valued at approximately $143,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at USANA Health Sciences
In related news, CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at $463,150.52. This trade represents a 24.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joshua Foukas sold 5,732 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders sold a total of 15,920 shares of company stock valued at $500,285 in the last quarter. Corporate insiders own 0.63% of the company's stock.
USANA Health Sciences Stock Performance
Shares of NYSE USNA traded down $0.25 during midday trading on Thursday, reaching $27.84. 21,537 shares of the company's stock were exchanged, compared to its average volume of 123,512. USANA Health Sciences, Inc. has a 52-week low of $23.10 and a 52-week high of $49.78. The business's fifty day moving average price is $27.62 and its two-hundred day moving average price is $33.05. The stock has a market capitalization of $525.06 million, a PE ratio of 9.84, a price-to-earnings-growth ratio of 0.93 and a beta of 1.00.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. During the same period last year, the firm posted $0.86 earnings per share. Analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have recently commented on USNA shares. DA Davidson cut their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.
Read Our Latest Research Report on USNA
USANA Health Sciences Profile
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
